spinosyn d
Description
spinosyn D: a macrolide, structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
spinosyn D : A spinosyn in which the sugar amino and hydroxy groups are globally methylated with an additional methyl substituent attached to the tetracyclic skeleton. One of the two active ingredients of spinosad. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 183094 |
CHEMBL ID | 503450 |
CHEBI ID | 9232 |
SCHEMBL ID | 465825 |
MeSH ID | M0296063 |
Synonyms (27)
Synonym |
---|
spinosad factor d |
spinosyn d |
131929-63-0 |
(2s,3ar,5as,5bs,9s,13s,14r,16as,16bs)-13-{[(2r,5s,6r)-5-(dimethylamino)-6-methyltetrahydro-2h-pyran-2-yl]oxy}-9-ethyl-4,14-dimethyl-7,15-dioxo-2,3,3a,5a,5b,6,7,9,10,11,12,13,14,15,16a,16b-hexadecahydro-1h-as-indaceno[3,2-d]oxacyclododecin-2-yl 6-deoxy-2,3 |
a 83543d |
CHEBI:9232 , |
CHEMBL503450 |
1h-as-indaceno(3,2-d)oxacyclododecin-7,15-dione, 2-((6-deoxy-2,3,4-tri-o- methyl-a-l-mannopyranosyl)oxy)-13-(((2r,5s,6r)-5- (dimethylamino)tetrahydro-6-methyl-2h-pyran-2-yl)oxy)-9-ethyl- 2,3,3a,5a,5b,6,9,10,11,12,13,14,16a,16b-tetradecahydro-4,14-dimethyl |
unii-78g4631rtt |
1h-as-indaceno(3,2-d)oxacyclododecin-7,15-dione, 2-((6-deoxy-2,3,4-tri-o-methyl-alpha-l-mannopyranosyl)oxy)-13-(((2r,5s,6r)-5-(dimethylamino)tetrahydro-6-methyl-2h-pyran-2-yl)oxy)-9-ethyl-2,3,3a,5a,5b,6,9,10,11,12,13,14,16a,16b-tetradecahydro-4,14-dimethy |
(2r,3as,5ar,5bs,9s,13s,14r,16as,16br)-2-((6-deoxy-2,3,4-tri-o-methyl-alpha-l-mannopyranosyl)oxy)-13-(((2r,5s,6r)-5-(dimethylamino)tetrahydro-6-methyl-2h-pyran-2-yl)oxy)-9-ethyl-4,14-dimethyl-2,3,3a,5a,5b,6,9,10,11,12,13,14,16a,16b-tetradecahydro-1h-as-ind |
spinosad factor d [usan] |
78g4631rtt , |
1h-as-indaceno(3,2-d)oxacyclododecin-7,15-dione, 2-((6-deoxy-2,3,4-tri-o-methyl-alpha-l-mannopyranosyl)oxy)-13-(((2r,5s,6r)-5-(dimethylamino)tetrahydro-6-methyl-2h-pyran-2-yl)oxy)-9-ethyl-2,3,3a,5a,5b,6,9,10,11,12,13,14,16a,16b-tetradecahydro-4,14-dimet |
spinosyn d [mi] |
SCHEMBL465825 |
DTXSID3037599 |
J-006090 |
AKOS032946518 |
(1s,2s,5r,7s,9s,10s,14r,15s,19s)-15-[(2r,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-19-ethyl-4,14-dimethyl-7-[(2r,3r,4r,5s,6s)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy-20-oxatetracyclo[10.10.0.02,10.05,9]docosa-3,11-diene-13,21-dione |
Q27108325 |
1h-as-indaceno3,2-doxacyclododecin-7,15-dione, 2-(6-deoxy-2,3,4-tri-o-methyl-.alpha.-l-mannopyranosyl)oxy-13-(2r,5s,6r)-5-(dimethylamino)tetrahydro-6-methyl-2h-pyran-2-yloxy-9-ethyl-2,3,3a,5a,5b,6,9,10,11,12,13,14,16a,16b-tetradecahydro-4,14-dimethyl-, (2 |
XS175291 |
spinosyn d 100 microg/ml in acetonitrile |
HY-125326 |
CS-0090359 |
(2s,3ar,5as,5bs,9s,13s,14r,16as,16bs)-2-[(6-deoxy-2,3,4-tri-o-methyl-?-l-mannopyranosyl)oxy]-13-[[(2r,5s,6r)-5-(dimethylamino)tetrahydro-6-methyl-2h-pyran-2-yl]oxy]-9-ethyl-2,3,3a,5a,5b,6,9,10,11,12,13,14,16a,16b-tetradecahydro-4,14-dimethyl-1h-as-indacen |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Dairy cows were dosed for 28 days with spinosad at rates equivalent to 0, 1, 3, and 10 microg/g in the diet." | ( Residues of spinosad in meat, milk, and eggs. Dolder, SC; Gardner, RC; Robb, CK; Rutherford, BS; West, SD, 2000) | 0.31 |
Roles (1)
Role | Description |
---|---|
pediculicide | Substance used to treat lice (genus Pediculus) infestation. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
Class | Description |
---|---|
spinosyn | A family of macrolide natural products produced by the soil microorganism Saccharopolyspora spinosa. |
spinosyn insecticide | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (4)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID379886 | Insecticidal activity against cotton aphid assessed as count of nonwinged stage live aphid after 72 hrs with 24 hrs of photoperiod prior to grading | 2006 | Journal of natural products, Dec, Volume: 69, Issue:12 | Engineering of the spinosyn PKS: directing starter unit incorporation. |
AID379887 | Insecticidal activity against green peach aphid assessed as count of nonwinged stage live aphid after 72 hrs with 24 hrs of photoperiod prior to grading | 2006 | Journal of natural products, Dec, Volume: 69, Issue:12 | Engineering of the spinosyn PKS: directing starter unit incorporation. |
AID379888 | Insecticidal activity against sweet potato whitefly assessed as larval survival after 13 days | 2006 | Journal of natural products, Dec, Volume: 69, Issue:12 | Engineering of the spinosyn PKS: directing starter unit incorporation. |
AID379892 | Insecticidal activity against two-spotted spinder mites assessed as count of live mites after 4 days with low light condition | 2006 | Journal of natural products, Dec, Volume: 69, Issue:12 | Engineering of the spinosyn PKS: directing starter unit incorporation. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (26)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (3.85) | 18.2507 |
2000's | 13 (50.00) | 29.6817 |
2010's | 10 (38.46) | 24.3611 |
2020's | 2 (7.69) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 27.81
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.81) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (3.85%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 25 (96.15%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |